TICKERNERD
Menu
LCTXLCTXHealthcare · Biotechnology

LCTX Stock Forecast: Lineage Cell Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$1.11
+2.78% on the day

The 7 Wall Street analysts covering Lineage Cell Therapeutics, Inc. hold a median 12-month price target of $4.5 — +305.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$269.2M
Ticker Nerd rank
66 / 100
Median analyst target
$4.50
Analysts covering
7
Total return, dividends reinvested
1W
+7.8%
1M
−17.8%
YTD
−33.5%
1Y
+12.1%
From 52W high
−43.4%
From 52W low
+16.8%
$0.95
$1.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LCTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lineage Cell Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Value
71
Volatility
69
Momentum
65
Size
63
Quality
59
Growth
48
Revisions
35
Issuance
32

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Lineage Cell Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

LCTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LCTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26LCTXHigh $9.00Median $4.50Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $3.00Median $4.50High $9.00

The green dot is the last close — the median target sits +305.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 July 2026HC Wainwright & Co.ReiteratesBuy—
4 May 2026D. Boral CapitalMaintainsBuy—
28 Apr 2026Canaccord GenuityInitiatesBuy—
25 Mar 2026B. Riley SecuritiesMaintainsBuy—
24 Mar 2026HC Wainwright & Co.ReiteratesBuy—
6 Mar 2026D. Boral CapitalMaintainsBuy—
9 Feb 2026D. Boral CapitalMaintainsBuy—
25 Nov 2025D. Boral CapitalMaintainsBuy—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
27 Aug 2025D. Boral CapitalMaintainsBuy—
14 Aug 2025D. Boral CapitalMaintainsBuy—
5 Aug 2025D. Boral CapitalMaintainsBuy—
23 June 2025D. Boral CapitalMaintainsBuy—
23 June 2025HC Wainwright & Co.ReiteratesBuy—
14 Mar 2025B. Riley SecuritiesMaintainsBuy—
11 Mar 2025D. Boral CapitalMaintainsBuy—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Feb 2025D. Boral CapitalMaintainsBuy—
11 Feb 2025HC Wainwright & Co.ReiteratesBuy—
31 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

LCTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Lineage Cell Therapeutics, Inc. (LCTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.9×

Cheaper than 88% of US stocks

Price / sales
18.2×

Cheaper than 10% of US stocks

Price / book
5.0×

Cheaper than 21% of US stocks

EV / EBITDA
−9.8×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
14.8%

Higher than 65% of US stocks

Earnings growth (YoY)
14.8%

Higher than 56% of US stocks

Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
−440.2%

Higher than 8% of US stocks

Net margin
99.0%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−98.2%

Higher than 13% of US stocks

Return on assets
−12.9%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LCTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LCTXLineage Cell Therapeutics, Inc.$269.2M
66
SLGLSol-Gel Technologies Ltd.$268.9M
53
NAGENiagen Bioscience, Inc.$271.2M
52
IMRXImmuneering Corp.$266.7M
56
FHTXFoghorn Therapeutics, Inc.$265.4M
63
SABSSAB Biotherapeutics, Inc.$273.0M
33
FULCFulcrum Therapeutics, Inc.$273.1M
39
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LCTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest LCTX news & analysis

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Business Wire · 30 July 2026neutral

Lineage Cell Therapeutics announced it will report its second quarter 2026 financial and operating results on August 6, 2026, after market close, and will host a conference call and webcast at 4:30 p.m. Eastern Time that day.

Why it matters — Investors and analysts tracking LCTX will be able to review the company's financial performance and receive a business update directly from management during the upcoming call.

FAQ

Frequently asked questions about LCTX stock

What is the LCTX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Lineage Cell Therapeutics, Inc. have a median 12-month price target of $4.5, with estimates ranging from $3 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LCTX stock a buy right now?

Of the 7 analysts covering Lineage Cell Therapeutics, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lineage Cell Therapeutics, Inc. 66 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LCTX?

As at 1 Aug 2026, Lineage Cell Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will LCTX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +305.4% from the last close, and Ticker Nerd's factor model ranks Lineage Cell Therapeutics, Inc. 66 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LCTX stock forecast for 2030?

No analyst covering Lineage Cell Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LCTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $9 over the next 12 months.

How has LCTX stock performed over the past year?

Lineage Cell Therapeutics, Inc. returned +12.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lineage Cell Therapeutics, Inc. do?

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel allogeneic, or off‑the‑shelf, cell therapies for serious neurological and ophthalmic conditions.

What is the latest news on LCTX?

The most recent item we track (Business Wire, 30 July 2026): "Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026". Lineage Cell Therapeutics announced it will report its second quarter 2026 financial and operating results on August 6, 2026, after market close, and will host a conference call and webcast at 4:30 p.m. Eastern Time that day.

Company

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel allogeneic, or off‑the‑shelf, cell therapies for serious neurological and ophthalmic conditions. The company leverages a proprietary cell-based technology platform and in-house development and manufacturing capabilities to design, produce, and test specialized human cells with anatomical and physiological functions similar to those found naturally in the body. These cells are generated from well-characterized pluripotent cell lines using directed differentiation processes, then transplanted to replace or support cells lost or damaged by degenerative disease, aging, or traumatic injury. Lineage Cell Therapeutics’ pipeline includes programs targeting dry age-related macular degeneration through retinal pigment epithelium cell replacement, spinal cord injury via oligodendrocyte progenitor cell therapy, oncology applications using dendritic cell vaccines, and additional preclinical candidates in hearing loss and vision restoration. Headquartered in Carlsbad, California, and founded in 1990, the company operates within the biopharmaceutical and medical research ecosystem, collaborating with larger industry partners to advance its cell therapy candidates toward broader clinical use.

CEO Mr. Brian M. Culley M.A., M.B.A. · 70 employees · United States · https://www.lineagecell.com